Skip to main content
. 2020 Jun 22;117(27):16009–16018. doi: 10.1073/pnas.1920483117

Fig. 3.

Fig. 3.

Oral administration of the OATP2B1 transport excipient inhibitor FD&C Red No. 40 reduces fexofenadine bioavailability in mice. (A) Plasma concentration–time profiles of fexofenadine after oral administration of 15 mg/kg fexofenadine with saline (blue circles, n = 8), 2.5 mg/kg FD&C Red No. 40 (green squares, n = 4), or 25 mg/kg FD&C Red No. 40 (red triangles, n = 9) to Pgp-deficient (mdr1a/b−/−) mice. Each point represents the mean ± SEM. (B–D) Pharmacokinetic parameters calculated using Phoenix WinNonlin v8.1: (B) plasma fexofenadine AUC0–120min, (C) plasma fexofenadine AUC0–360min, and (D) maximum plasma concentration (Cmax). Each point represents the data from an individual mouse administered with 15 mg/kg fexofenadine plus saline (blue; n = 8), fexofenadine plus 2.5 mg/kg FD&C Red No. 40 (green; n = 4), and fexofenadine plus 25 mg/kg FD&C Red No. 40 (red; n = 9). *P < 0.05, **P < 0.01; ANOVA with Tukey’s correction.